IL2 and type 1 diabetes mellitus: The statistical design of the DILT1D phase I study required a relatively large number of participants (N = 45) to be recruited to complete the study, compared to previous early phase studies of IL-2 therapy in T1D (N = 25) [20] and healthy individuals (N = 22) [21].